

DIAGNOCURE TO HOST Q3 2010 EARNINGS CONFERENCE CALL AND WEBCAST

QUEBEC CITY, August 31, 2010 — DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its third quarter 2010 results on September 13, 2010, at approximately 4:30 p.m. (EDT). This release will be followed by a conference call, which will be held on September 14, 2010, at 10:00 a.m. (EDT). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page – Presentations.

For those who wish to take part in the conference call for the Q&A period, please dial the toll-free number 1-888-231-8191 and provide the subject «DiagnoCure Q3 Earnings Announcement, Conference number 98090465».

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of September 15, 2010, also through a link on the Investors page – Presentations.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure, Inc., launched in 2008 the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. A major study published in the February 18, 2009, edition of the *Journal of the American Medical Association* demonstrated that GCC, to which DiagnoCure owns exclusive worldwide diagnostic rights, is the strongest independent predictor of colorectal cancer recurrence. More clinical studies are underway to confirm the clinical utility of the Previstage™ GCC test. The Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is available through laboratories in the U.S. and in Canada using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGNSA® PCA3 *in vitro* assay. Gen-Probe recently completed a 500-patient clinical study aimed at securing FDA approval for the commercialization of the PROGNSA® PCA3 test in the U.S. and is on target to file a PMA by the end of the year. For more information, visit www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein unless required by the applicable securities laws and regulations.

-30-

Contacts:

Investors

DiagnoCure Inc.

Chantal Miklosi

Chief Financial Officer

(418) 527-6100

communications@diagnocure.com

Media

DiagnoCure Inc.

Paule De Blois

Sr. Vice President, Operations

(418) 527-6100